Oncology News | pharmaphorum

News

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.

News

In a class first, Merck's Keytruda extends survival in cervi...

Merck & Co's Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live longer when used as alongside standard first-line drugs.

News

BioNTech takes its first cancer vaccine into phase 2

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

News

BMS pays $650m upfront for Eisai's first ADC candidate for c...

Japan's Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing deal from Bristol-Myers Squibb that could top out at more than $3.

News

Gilead combs Shoreline for NK cell therapies in $2.3bn allia...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing

News

Ambrx tries another IPO as it chases down HER2 rivals

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, it

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

In a class first, Merck's Keytruda extends survival in cervi...

BioNTech takes its first cancer vaccine into phase 2

BMS pays $650m upfront for Eisai's first ADC candidate for c...

Gilead combs Shoreline for NK cell therapies in $2.3bn allia...

Ambrx tries another IPO as it chases down HER2 rivals

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks